Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash & Equivalents (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Cash & Equivalents for 6 consecutive years, with $84.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 32.4% to $84.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $84.0 million, a 32.4% decrease, with the full-year FY2025 number at $84.0 million, down 32.4% from a year prior.
  • Cash & Equivalents was $84.0 million for Q4 2025 at Relay Therapeutics, down from $91.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $354.6 million in Q3 2022 to a low of $84.0 million in Q4 2025.
  • A 5-year average of $165.7 million and a median of $148.6 million in 2023 define the central range for Cash & Equivalents.
  • Biggest YoY gain for Cash & Equivalents was 273.49% in 2021; the steepest drop was 59.13% in 2021.
  • Relay Therapeutics' Cash & Equivalents stood at $280.1 million in 2021, then crashed by 45.81% to $151.8 million in 2022, then decreased by 5.31% to $143.7 million in 2023, then fell by 13.53% to $124.3 million in 2024, then crashed by 32.4% to $84.0 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Cash & Equivalents are $84.0 million (Q4 2025), $91.6 million (Q3 2025), and $113.9 million (Q2 2025).